PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20883052-7	2010	Glycosylated haemoglobin, fasting glucose, insulin parameters and beta-cell function are all improved with pioglitazone treatment, with efficacy similar to third-generation sulfonylureas, metformin and dipeptidyl peptidase-4 inhibitors.	Pioglitazone	107-119	dipeptidyl peptidase 4	Homo sapiens	202-224	
21651446-2	2011	Pioglitazone is now the only thiazolidinedione approved for the treatment of T2DM and can be administered in combination with metformin, sulfonylureas, exenatide, dipeptidyl peptidase 4 (DPP-4) inhibitors or insulin.	Pioglitazone	0-12	dipeptidyl peptidase 4	Homo sapiens	163-185	
21651446-2	2011	Pioglitazone is now the only thiazolidinedione approved for the treatment of T2DM and can be administered in combination with metformin, sulfonylureas, exenatide, dipeptidyl peptidase 4 (DPP-4) inhibitors or insulin.	Pioglitazone	0-12	dipeptidyl peptidase 4	Homo sapiens	187-192	
21595275-3	2011	Pioglitazone, a thiazolidinedione class agent, is an insulin sensitizer and alogliptin belongs to DPP-4 (dipeptidyl peptidase-4) inhibitor class agents, which promote postprandial insulin secretion and suppress glucagon secretion in a blood glucose dependent fashion.	Pioglitazone	0-12	dipeptidyl peptidase 4	Homo sapiens	105-127	
19259628-0	2009	DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy.	Pioglitazone	68-80	dipeptidyl peptidase 4	Homo sapiens	0-4	
20875371-0	2010	Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteers.	Pioglitazone	107-119	dipeptidyl peptidase 4	Homo sapiens	58-80	
18793589-0	2008	Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes.	Pioglitazone	136-148	dipeptidyl peptidase 4	Homo sapiens	74-97	
33172034-5	2020	Subgroup analysis found lower MACCEs risk in the pioglitazone users without insulin therapy (6.44% vs. 10.04% (HR): 0.59, 95% (CI): 0.42-0.82) and lower MACCEs related death (2.76% vs. 3.84% (HR): 0.61, 95% (CI): 0.40-0.95) in the pioglitazone group with dyslipidemia, when comparing with DPP4-inhibitors users.	Pioglitazone	49-61	dipeptidyl peptidase 4	Homo sapiens	289-293	
27429679-6	2016	The number of subjects who had taken high-dose metformin (>= 1,000 mg) and dipeptidyl peptidase-4 (DPP-4) inhibitors increased after the withdrawal or dose reduction of pioglitazone in both groups.	Pioglitazone	172-184	dipeptidyl peptidase 4	Homo sapiens	78-100	
31880221-12	2020	In the subgroup analysis, DPP-4 inhibitors first had lower (2010: OR = 0.78, 95% CI = 0.70-0.87; 2011-2012: OR = 0.60, 95% CI = 0.54-0.66) and then similar (2013-2014: OR = 1.03, 95% CI = 0.88-1.19) hazards of nonpersistence compared with pioglitazone.	Pioglitazone	239-251	dipeptidyl peptidase 4	Homo sapiens	26-31	
31880221-15	2020	Similarly, safety warnings in 2011 and approval of generic products in 2012 may have affected pioglitazone persistence, leading to first higher and then similar hazards for nonpersistence with pioglitazone as compared with DPP-4 inhibitors.	Pioglitazone	94-106	dipeptidyl peptidase 4	Homo sapiens	223-228	
31087620-8	2019	However, the HR was 1.20 (1.01-1.42) when cohorts were restricted to new users, censored upon treatment change, and when DPP-4 was used as the referent, suggesting an increased risk of bladder cancer associated with pioglitazone.	Pioglitazone	216-228	dipeptidyl peptidase 4	Homo sapiens	121-126	
30663560-4	2020	Regarding antidiabetic medication, metformin, gliclazide, pioglitazone, exenatide and dapagliflozin exert a beneficial effect on Endothelial Function (EF); glimepiride and glibenclamide, dipeptidyl peptidase-4 inhibitors and liraglutide have a neutral effect, while studies examining the effect of insulin analogues, empagliflozin and canagliflozin on EF are limited.	Pioglitazone	58-70	dipeptidyl peptidase 4	Homo sapiens	187-209	
29138876-6	2018	RESULTS: Individuals aged >=65 years on metformin + pioglitazone had a significantly lower risk of dementia compared with those on metformin + sulfonylurea (HR 0.56; 95% CI 0.34, 0.93), and a lower, but insignificant, risk of dementia compared with those on other metformin-based dual regimens (i.e. metformin + acarbose, metformin + meglitinide, metformin + insulin or metformin + dipeptidyl peptidase 4 inhibitors).	Pioglitazone	55-67	dipeptidyl peptidase 4	Homo sapiens	385-407	
27429679-6	2016	The number of subjects who had taken high-dose metformin (>= 1,000 mg) and dipeptidyl peptidase-4 (DPP-4) inhibitors increased after the withdrawal or dose reduction of pioglitazone in both groups.	Pioglitazone	172-184	dipeptidyl peptidase 4	Homo sapiens	102-107	
24824197-1	2014	AIMS: To investigate the efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in patients with Type 2 diabetes mellitus inadequately controlled by a combination of metformin and pioglitazone.	Pioglitazone	197-209	dipeptidyl peptidase 4	Homo sapiens	52-74	
22192641-0	2012	Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase IV inhibitor LC15-0444 and pioglitazone in healthy volunteers.	Pioglitazone	106-118	dipeptidyl peptidase 4	Homo sapiens	58-81